X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (510) 510
Publication (50) 50
Book Chapter (7) 7
Book / eBook (4) 4
Book Review (3) 3
Dissertation (2) 2
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (292) 292
male (161) 161
middle aged (161) 161
hematology (160) 160
female (156) 156
adult (118) 118
index medicus (117) 117
aged (115) 115
oncology (114) 114
multiple myeloma (103) 103
multiple myeloma - drug therapy (82) 82
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
chemotherapy (68) 68
treatment outcome (67) 67
prognosis (66) 66
bortezomib (65) 65
transplantation, autologous (64) 64
multiple myeloma - therapy (62) 62
antineoplastic agents - therapeutic use (50) 50
stem-cell transplantation (50) 50
multiple myeloma - mortality (48) 48
survival (47) 47
disease-free survival (46) 46
transplantation (45) 45
recurrence (41) 41
retrospective studies (41) 41
survival analysis (41) 41
adolescent (39) 39
multiple myeloma - genetics (39) 39
remission induction (38) 38
therapy (37) 37
cancer (36) 36
combined modality therapy (34) 34
survival rate (34) 34
hematopoietic stem cell transplantation (32) 32
thalidomide (32) 32
aged, 80 and over (31) 31
stem cell transplantation (31) 31
multiple myeloma - pathology (30) 30
hematopoietic stem cell transplantation - methods (27) 27
life sciences (27) 27
hematology, oncology and palliative medicine (26) 26
high-dose therapy (26) 26
abridged index medicus (25) 25
bone-marrow-transplantation (25) 25
boronic acids - therapeutic use (24) 24
immunology (24) 24
pyrazines - therapeutic use (24) 24
time factors (24) 24
tumor cells, cultured (24) 24
antineoplastic combined chemotherapy protocols - administration & dosage (23) 23
dexamethasone (23) 23
leukemia (23) 23
risk factors (23) 23
transplantation, homologous (23) 23
autologous transplantation (22) 22
dexamethasone - administration & dosage (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (21) 21
expression (21) 21
antineoplastic agents - adverse effects (20) 20
bone marrow transplantation (20) 20
disease progression (20) 20
follow-up studies (20) 20
melphalan (20) 20
multiple-myeloma (20) 20
thalidomide - administration & dosage (20) 20
translocation, genetic (20) 20
autologous stem cell transplantation (19) 19
boronic acids - administration & dosage (19) 19
pyrazines - administration & dosage (19) 19
care and treatment (18) 18
lenalidomide (18) 18
medicine, general & internal (18) 18
multiple myeloma - immunology (18) 18
stem cells (18) 18
thalidomide - analogs & derivatives (18) 18
thalidomide - therapeutic use (18) 18
trial (18) 18
antineoplastic agents - administration & dosage (17) 17
doxorubicin - administration & dosage (17) 17
child (16) 16
in-situ hybridization (16) 16
leukemia, myeloid, acute - drug therapy (16) 16
neoplasm staging (16) 16
prospective studies (16) 16
salvage therapy (16) 16
acute myeloid-leukemia (15) 15
bone-marrow transplantation (15) 15
boronic acids - adverse effects (15) 15
in situ hybridization, fluorescence (15) 15
melphalan - administration & dosage (15) 15
multiple myeloma - diagnosis (15) 15
multiple myeloma - metabolism (15) 15
pyrazines - adverse effects (15) 15
bone-marrow (14) 14
clinical trials as topic (14) 14
lenalidomide plus dexamethasone (14) 14
multivariate analysis (14) 14
randomized-trial (14) 14
thalidomide - adverse effects (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. e328 - e346
Journal Article
2007, Best practice & research. Clinical haematology, Volume 20, no. 4., 569-835i
Book
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
In this trial, 700 patients with myeloma were randomly assigned to receive RVD therapy (lenalidomide, bortezomib, and dexamethasone) with or without autologous... 
DIAGNOSED MULTIPLE-MYELOMA | MEDICINE, GENERAL & INTERNAL | PHASE-III | AUTOLOGOUS TRANSPLANTATION | DARATUMUMAB MONOTHERAPY | INITIAL TREATMENT | FOLLOW-UP | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Life Sciences | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4621 - 4629
Journal Article
The Oncologist, ISSN 1083-7159, 2010, Volume 15, Issue 1, pp. 6 - 25
Journal Article